Studies on Aconitum Species. XV. Deoxygenation Reaction of Aconitine Type Alkaloids

Takao Mori, Mitsuo Murayama, *. Hideo Bando and Norio Kawahara *

Research Sections, Sanwa Shoyaku Co., Ltd., ^a 6–1, Hiraide Kogyo Danchi, Utsunomiya 321, Japan and Hokkaido Institute of Pharmaceutical Sciences, ^b 7–1, Katsuraoka-cho, Otaru 047–02, Japan. Received March 20, 1991

Mesaconitine (1) in tetrahydrofuran reacted with sodium hydride, a catalytic amount of imidazole, carbon disulfide and methyl iodide at room temperature to give the di-O-(S-methyl)thiocarbonate (5). The reductive cleavage of 5 with tri-n-butyltin hydride gave isodelphinine (3) in a high yield of 83%. The exact same reactions of aconitine (2) and jesaconitine (6) gave penduline (4) and 3,13-dideoxyjesaconitine (7) in 85 and 86% yields, respectively. The same reactions in diethylether, in place of tetrahydrofuran, gave the 3-deoxy compounds, hypaconitine (9), deoxyaconitine (10) and deoxyjesaconitine (11), in yields of 87, 88 and 85%, respectively. When the same reaction as used for the syntheses of the 3,13-dideoxy compounds was done at refluxing temperature, 3,13,15-trideoxy compounds, that is, 3,13,15-trideoxymesaconitine, 3,13,15-trideoxyaconitine and 3,13,15-trideoxyjesaconitine, were obtained in yields of 83, 83 and 88%, respectively.

Keywords aconitine; deoxygenation; mesaconitine; jesaconitine; hypaconitine

Aconitine type alkaloids are highly oxygenated compounds and studies on the reactivity of their oxygen functions, as well as chemical correlations and structure—activity relationships, are important in order to understand their potent biological activities.

In 1988, Kulanthaivel and Pelletier¹⁾ reported on the deoxygenation of several C19 diterpenoid alkaloids by using reductive cleavage of imidazolylthiocarbonylester with tri-n-butyltin hydride (n-Bu₃SnH). However, there have been few reports of deoxygenation reactions of aconitine-type alkaloids. We reported previously on the transformation of mesaconitine (1) and aconitine (2) into isodelphinine (3) and penduline (4), respectively, by deoxygenation of a C13-O-triflate by means of photochemical cleavage.²⁻⁴⁾ But the yield of the photochemical deoxygenation was low. Further, synthesis of compounds deoxygenated at C3, C13 and C15 is necessary to investigate the structure–activity relationships.

In this paper, we present high-yield deoxygenations at C3, C13 and C15 of aconitine-type alkaloids according to Barton and McCombic.⁵⁾

Treatment of 1 with sodium hydride (NaH) in the presence of a catalytic amount of imidazole in tetra-

hydrofuran (THF), followed by the addition of carbon disulfide (CS₂) and methyl iodide (CH₃I) at room temperature, gave 3,13-di-O-(S-methyl)thiocarbonate (5) in 96% yield. The proton nuclear magnetic resonance (¹H-NMR) spectrum of 5 revealed the presence of two S-methyl groups, at $\delta 2.57$ and 2.46. The signal at $\delta 5.70$ (1H, J=12.7, 5.5 Hz) assignable to C3- β -H suggested the presence of a thiocarbonyloxy group at C3, and the ¹³Cnuclear magnetic resonance (13C-NMR) spectrum suggested the presence of another thiocarbonyloxy group at C13. The other signals and the mass (MS) spectrum were in agreement with the assigned structure. The reductive cleavage of 5 with n-Bu₃SnH gave 3 in a yield of 83%. This product was identical with an authentic sample²⁾ in terms of melting point and (NMR), infrared (IR), and MS spectra.

Application of this methodology to **2** gave **4** in a yield of 85%. This product was identical with an authentic sample³⁾ in terms of melting point and NMR, IR and MS spectra.

Jesaconitine (6) gave 3,13-dideoxyjesaconitine (7) by the above method in an 86% overall yield. Synthesis of the 3,13-dideoxy compound has not previously been reported,

$$\begin{array}{c} OCH_3 \\ OCH_3 \\ \hline \\ R_1O \\ \hline \\ OCH_3 \\ \hline \end{array}$$

```
2: R<sub>1</sub> = H, R<sub>2</sub> = H, R<sub>3</sub> = Bz, R<sub>4</sub> = H, R<sub>5</sub> = CH<sub>2</sub>CH<sub>3</sub>
5: R<sub>1</sub> = CS(SCH<sub>3</sub>), R<sub>2</sub> = CS(SCH<sub>3</sub>), R<sub>3</sub> = Bz, R<sub>4</sub> = H, R<sub>5</sub> = CH<sub>3</sub>
6: R<sub>1</sub> = H, R<sub>2</sub> = H, R<sub>3</sub> = As, R<sub>4</sub> = H, R<sub>5</sub> = CH<sub>2</sub>CH<sub>3</sub>
8: R<sub>1</sub> = CS(SCH<sub>3</sub>), R<sub>2</sub> = H, R<sub>3</sub> = Bz, R<sub>4</sub> = H, R<sub>5</sub> = CH<sub>3</sub>
12: R<sub>1</sub> = CS(SCH<sub>3</sub>), R<sub>2</sub> = CS(SCH<sub>3</sub>), R<sub>3</sub> = As, R<sub>4</sub> = CS(SCH<sub>3</sub>), R<sub>5</sub> = CH<sub>2</sub>CH<sub>3</sub>
14: P<sub>1</sub> = CS(SCH<sub>3</sub>), P<sub>2</sub> = CS(SCH<sub>3</sub>), P<sub>3</sub> = P<sub>3</sub>, P<sub>4</sub> = H, P<sub>5</sub> = CH<sub>2</sub>CH<sub>3</sub>
```

14: $R_1 = CS(SCH_3)$, $R_2 = CS(SCH_3)$, $R_3 = Bz$, $R_4 = H$, $R_5 = CH_2CH_3$ 15: $R_1 = CS(SCH_3)$, $R_2 = CS(SCH_3)$, $R_3 = As$, $R_4 = H$, $R_5 = CH_2CH_3$

16: $R_1 = CS(SCH_3)$, $R_2 = H$, $R_3 = Bz$, $R_4 = H$, $R_5 = CH_2CH_3$

17: $R_1 = CS(SCH_3)$, $R_2 = H$, $R_3 = As$, $R_4 = H$, $R_5 = CH_2CH_3$

 $R_1 = H, R_2 = H, R_3 = Bz, R_4 = H, R_5 = CH_3$

18: $R_1 = CS(SCH_3)$, $R_2 = CS(SCH_3)$, $R_3 = Bz$, $R_4 = CS(SCH_3)$, $R_5 = CH_2CH_3$

20: $R_1 = CS(SCH_3)$, $R_2 = CS(SCH_3)$, $R_3 = Bz$, $R_4 = CS(SCH_3)$, $R_5 = CH_3$

Chart 1

© 1991 Pharmaceutical Society of Japan

Chart 2

and its structure was determined by analysis of the spectral data (see Experimental).

These results indicate that the deoxygenation procedure leads to the production of 3,13-dideoxygenated derivatives in considerable yield. Meanwhile, deoxygenation at C3 alone could also be performed by using diethyl ether instead of THF as a reaction solvent to give the 3-O-(S-methyl)thiocarbonate (8) of 1 in a yield of 93%. The 1 H-NMR spectrum of 8 showed a signal at δ 5.72 (dd, J=12.7, 5.4 Hz) assignable to C3- β -H. Other NMR and MS signals of 8 were in agreement with the assigned structure. Reductive cleavage of 8 with n-Bu₃SnH gave hypaconitine (9) in a yield of 87%. This product was identical with an authentic sample in terms of melting point and NMR, IR and MS spectra.

Application of the deoxygenation sequence to 2 and 6 gave deoxyaconitine (10) and deoxyjesaconitine (11) in overall yields of 88 and 85%, respectively. These transformation processes occur in considerably superior yields to those previously obtained.⁷⁾

Lastly, deoxygenation at C3, C13 and C15 was achieved as follows.

A hydroxy group at C15 in aconitine-type alkaloids generally resists acylation, since the hydroxy group is shielded by the aroyl group at C14 and the acetyl group at C8. A mixture of **6** with NaH and a catalytic amount of imidazole in THF was stirred for 0.5 h, followed by the addition of CS₂ and CH₃I at room temperature. The reaction mixture was refluxed for 1.5 h to give the 3,13,15-tri-O-(S-methyl)thiocarbonate (12) in a yield of 93%. In the 1 H-NMR spectrum of 12, three S-methyl signals were apparent, at δ 2.46, 2.57 and 2.66. Three (S-methyl)thiocarbonyloxy groups were concluded to be present at C3, C13 and C15 on the basis of the other 1 H-NMR signals and 1 3C-NMR chemical shifts (see Experimental).

Reductive cleavage of 12 with *n*-Bu₃SnH furnished 3,13,15-trideoxyjesaconitine (13) in a yield of 88%. Its melting point and spectral data were identical with those of foresaconitine isolated from *Aconitum forrestii*. ^{10,11} Application of the same deoxygenation sequence to 1 and 2 also gave the 3,13,15-trideoxycompounds (21, 19).

Experimental

All melting points are uncorrected. IR spectra were taken in KBr disks

with a JASCO FT/7000 spectrometer, and ultraviolet (UV) spectra were measured in EtOH solution with a Shimadzu UV 240 spectrophotometer. NMR spectra were measured in CDCl₃ solution with a JEOL GX-270, using tetramethylsilane as an internal standard. MS and high resolution mass spectra (HR-MS) were measured with a Hitachi M-2000 spectrometer. Column chromatography was performed on silica gel (0.06—0.200 mm, Merck). Preparative thin layer chromatography (TLC) was performed on Silica gel F₂₅₄ (thickness I mm, Merck).

3,13-Di-*O*-(*S*-methyl)thiocarbonylmesaconitine (5) A mixture of 1 (50 mg), dry THF (6 ml), imidazole (1.3 mg) and NaH (116 mg) was stirred at 0 °C for 30 min, then CS_2 (1.2 ml) and CH_3I (0.9 ml) were added dropwise. The mixture was stirred for 1.5 h at room temperature, then the reaction was quenched with ice-water and the whole was extracted with $CHCl_3$. The $CHCl_3$ extract was washed with water, then dried over anhydrous sodium sulfate. The solvent was evaporated off and the residue was purified by column chromatography on silica gel with Et_2O saturated with 28% ammonia water—hexane (3:2) as an eluting solvent to yield 5 (60 mg, 96%, amorphous). IR v_{max}^{KBr} cm⁻¹: 3450 (OH), 1715 (C=O). ^{1}H -NMR δ : 1.41 (3H, s, OCOCH₃), 2.38 (3H, s, NCH₃), 2.46 (3H, s, SCH₃), 2.57 (3H, s, SCH₃), 3.18 (3H, s, OCH₃), 3.21 (3H, s, OCH₃), 3.22 (3H, s, OCH₃), 3.58 (3H, s, OCH₃), 5.24 (1H, d, J=5.1 Hz, C14- β -H), 5.70 (1H, dd, J=12.7, 5.5 Hz, C3- β -H), 7.43—8.09 (5H, m, benzoyl group). ^{13}C -NMR δ : 18.8 and 19.4 (SCH₃ × 2), 81.9 (C3), 88.4 (C13), 213.9 and 214.9 (C=S × 2). MS m/z: 811 (M⁺), 780 (M⁺ – OCH₃, base peak), 720 (M⁺ – OCH₃ – CH₃COOH).

Isodelphinine (3) A solution of 5 (20 mg) in 1 ml of dry benzene was refluxed with $n\text{-Bu}_3\text{SnH}$ (0.15 ml) in dry benzene (0.5 ml) for 2 h. The reaction mixture was concentrated *in vacuo*, then the residue was chromatographed on silica gel with Et₂O saturated with 28% ammonia water–hexane (4:1) as an eluting solvent and crystallized from Et₂O-hexane to give 3 (12.3 mg, 83% yield): mp 159—161 °C (lit.⁴⁾ 158—160 °C). IR $v_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3500, 1720 and 1705 (C=O). ¹H-NMR δ: 1.43 (3H, s, OCOH₃), 2.35 (3H, s, NCH₃), 3.18 (3H, s, OCH₃), 3.28 (6H, s, OCH₃), 3.52 (3H, s, OCH₃), 5.05 (1H, t, J = 4.3 Hz, C14-β-H), 7.40—8.05 (5H, m, benzoyl group). MS m/z: 599 (M⁺), 568 (M⁺ – OCH₃), 508 (M⁺ – OCH₃, COH₃), base peak). The NMR and MS spectra of 3 were identical to those of an authentic sample.

3,13-Di-*O*-(*S*-methyl)thiocarbonylaconitine (14) Compound 14 was prepared from 2 in 93% yield in the same manner as used for the synthesis of compound 5: amorphous powder. IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3420 (OH), 1717 (C=O). ¹H-NMR δ : 1.12 (3H, t, J=7.1 Hz, NCH₂CH₃), 1.41 (3H, s, OCOCH₃), 2.45 (3H, s, SCH₃), 2.57 (3H, s, SCH₃), 3.18 (3H, s, OCH₃), 3.20 (3H, s, OCH₃), 3.26 (3H, s, OCH₃), 3.58 (3H, s, OCH₃), 5.24 (1H, d, J=5.1 Hz, C14- β -H), 5.71 (1H, dd, J=12.3, 5.5 Hz, C3- β -H), 7.45—8.07 (5H, m, benzoyl group). ¹³C-NMR δ : 18.9 and 19.3 (SCH₃×2), 81.6 (C3), 88.3 (C13), 213.9 and 215.0 (C=S ×2). MS m/z: 825 (M⁺), 794 (M⁺-OCH₃, base peak), 734 (M⁺-OCH₃-CH₃COOH).

Penduline (4) Compound **4** was prepared from **14** in 91% yield in the same manner as used for the synthesis of compound **3**: mp 165—166°C (acetone–hexane) (lit.⁴⁾ 166—167°C). IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3450 (OH), 1715 (C=O). ¹H-NMR δ: 1.06 (3H, t, J=7.0 Hz, NCH₂CH₃), 1.43 (3H, s, OCOCH₃), 3.18 (3H, s, OCH₃), 3.27 (3H, s, OCH₃), 3.28 (3H, s, OCH₃), 3.52 (3H, s, OCH₃), 5.05 (1H, t, J=4.5 Hz, C14-β-H), 7.38—8.14 (5H, m, benzoyl group). MS m/z: 613 (M⁺), 582 (M⁺-OCH₃), 522 (M⁺-OCH₃-CH₃COOH, base peak). The NMR and MS spectra of **4** were identical to those of an authentic sample.

3,13-Di-*O*-(*S*-methyl)thiocarbonyljesaconitine (15) Compound 15 was prepared from 6 in 96% yield in the same manner as used for the synthesis of compound 5: amorphous powder. IR $v_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3450 (OH), 1717 (C=O). ¹H-NMR δ: 1.12 (3H, t, J=7.1 Hz, NCH₂CH₃), 1.42 (3H, s, OCOCH₃), 2.46 (3H, s, SCH₃), 2.56 (3H, s, SCH₃), 3.18 (3H, s, OCH₃), 3.21 (3H, s, OCH₃), 3.25 (3H, s, OCH₃), 3.58 (3H, s, OCH₃), 3.87 (3H, s, OCH₃), 7.8 Hz, C3-β-H), 6.94 and 8.03 (each 2H, d, J=9.1 Hz, anisoyl group). ¹³C-NMR δ: 18.8 and 19.4 (SCH₃ × 2), 81.6 (C3), 88.4 (C13), 213.9 and 214.7 (C=S × 2). MS m/z: 855 (M⁺), 824 (M⁺-OCH₃, base peak), 764 (M⁺-OCH₃-CH₃COOH).

3,13-Dideoxyjesaconitine (7) Compound **7** was prepared from **15** in 89% yield in the same manner as used for the synthesis of compound **3**: amorphous powder. IR $v_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3425 (OH), 1711 (C=O). ¹H-NMR δ: 1.11 (3H, t, J=7.1 Hz, NCH₂CH₃), 1.42 (3H, s, OCOCH₃), 3.19 (3H, s, OCH₃), 3.21 (3H, s, OCH₃), 3.26 (3H, s, OCH₃), 3.58 (3H, s, OCH₃), 3.87 (3H, s, OCH₃ of anisoyl group), 5.06 (1H, t, J=4.5 Hz, C14- β -H), 6.96 and 8.05 (each 2H, d, J=9.0 Hz, anisoyl group). ¹³C-NMR δ: 85.1 (C1), 26.4 (C2), 34.8 (C3), 39.0 (C4), 49.0 (C5), 83.5 (C6), 44.3 (C7),

November 1991 2805

92.0 (C8), 45.3 (C9), 38.6 (C10), 50.0 (C11), 28.8 (C12), 44.5 (C13), 76.1 (C14), 75.4 (C15), 89.3 (C16), 61.5 (C17), 80.3 (C18), 53.2 (C19), 49.1 (NCH₂CH₃), 13.5 (NCH₂CH₃), 56.1 (C1'), 57.7 (C6'), 57.9 (C16'), 59.0 (C18'), 55.3 (COC₆H₄OCH₃), 172.2 (COCH₃), 21.3 (COCH₃), 166.0 (COC₆H₄OCH₃), 122.4, 131.6, 113.5 and 163.2 (COC₆H₄OCH₃). MS m/z: 643 (M⁺), 612 (M⁺-OCH₃, base peak), 552 (M⁺-OCH₃-CH₃COOH). Anal. Calcd for C₃₅H₄₉NO₁₀: C, 65.30; H, 7.67; N, 2.18. Found: C, 65.57; H, 7.84; N, 2.23.

3-O-(S-Methyl)thiocarbonylmesaconitine (8) A mixture of 1 (50 mg), dry Et₂O (6 ml), imidazole (3 mg) and NaH (116 mg) was stirred at 0 °C for 30 min, then CS₂ (1.2 ml) and CH₃I (0.9 ml) were added dropwise. The mixture was stirred for 2h at room temperature, then the reaction was guenched with ice-water and the whole was extracted with CHCl₂. The CHCl₃ extract was washed with water, then dried over anhydrous sodium sulfate. The solvent was evaporated off and the residue was purified by column chromatography on silica gel with Et₂O saturated with 28% ammonia water-hexane (3:2) as an eluting solvent to yield 8 (53 mg, 93%): amorphous powder. IR $v_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3370 (OH), 1710 (C=O). ¹H-NMR δ : 1.40 (3H, s, OCOCH₃), 2.44 (3H, s, NCH₃), 2.57 (3H, s, SCH₃), 3.18 (3H, s, OCH₃), 3.20 (3H, s, OCH₃), 3.28 (3H, s, OCH₃), 3.74 (3H, s, OCH₃), 4.88 (1H, d, J = 5.3 Hz, C14- β -H), 5.72 (1H, dd, J = 12.7, 5.4 Hz, C3-β-H), 8.05—7.43 (5H, m, benzoyl group). 13 C-NMR δ: 18.5 (SCH_3) , 81.7 (C3), 214.9 (C=S). MS m/z: 721 (M⁺), 690 (M⁺-OCH₃, base peak), 630 (M⁺-OCH₃-CH₃COOH).

Hypaconitine (9) A solution of **8** (20 mg) in 1 ml of dry benzene was refluxed with *n*-Bu₃SnH (0.15 ml) in dry benzene (0.5 ml) for 2 h. The reaction mixture was concentrated *in vacuo*, then the residue was chromatographed on silica gel with Et₂O saturated with 28% ammonia water–hexane (4:1) as an eluting solvent and crystalized from MeOH to give **9** (16 mg, 94% yield): mp 189—190 °C. IR $\nu_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3450 (OH), 1730 (C=O). ¹H-NMR δ: 1.39 (3H, s, OCOH₃), 2.35 (3H, s, NCH₃), 3.18 (3H, s, OCH₃), 3.33 (6H, s, OCH₃×2), 3.75 (3H, s, OCH₃), 4.87 (1H, d, J=5.0 Hz, C14-β-H), 8.05—8.12 (5H, m, benzoyl group). MS m/z: 615 (M⁺), 584 (M⁺ – OCH₃, base peak), 524 (M⁺ – OCH₃–CH₃COOH). *Anal*. Calcd for C₃₃H₄₅NO₁₀: C, 64.37; H, 7.37; N, 2.27. Found: C, 64.49; H, 7.42; N, 2.26. The NMR and MS spectra of **9** were identical to those of an authentic sample.

3-O-(S-Methyl)thiocarbonylaconitine (16) Compound **16** was prepared from **2** in 92% yield in the same manner as used for the synthesis of compound **8**: amorphous powder. IR $v_{\rm max}^{\rm KBr}$ cm⁻¹: 3450 (OH), 1725 (C=O). ¹H-NMR δ: 1.16 (3H, t, J=7.1 Hz, NCH₂CH₃), 1.39 (3H, s, OCOCH₃), 2.56 (3H, s, SCH₃), 3.19 (3H, s, OCH₃), 3.20 (3H, s, OCH₃), 3.74 (3H, s, OCH₃), 4.88 (1H, d, J=4.9 Hz, C14- β -H), 5.71 (1H, dd, J=12.1, 6.8 Hz, C3- β -H), 7.4—8.02 (5H, m, benzoyl group). ¹³C-NMR δ: 18.7 (SCH₃), 81.6 (C3), 214.7 (C=S). MS m/z: 735 (M⁺), 704 (M⁺-OCH₃, base peak), 644 (M⁺-OCH₃-CH₃COOH).

Deoxyaconitine (10) Compound **10** was prepared from **16** in 96% yield in the same manner as used for the synthesis of compound **9**: colorless needles (MeOH), mp 169.5—170.5 °C (lit.⁶) 168—170 °C). IR $\nu_{\rm max}^{\rm KBr}$ cm⁻¹: 3550 (OH), 1730 and 1715 (C=O). ¹H-NMR δ: 1.07 (3H, t, J=7.0 Hz, NCH₂CH₃), 1.37 (3H, s, OCOCH₃), 3.15 (3H, s, OCH₃), 3.26 (3H, s, OCH₃), 3.28 (3H, s, OCH₃), 3.73 (3H, s, OCH₃), 4.87 (1H, d, J=5.0 Hz, C14-β-H), 7.32—8.12 (5H, m, benzoyl group). MS m/z: 629 (M⁺), 598 (M⁺ –OCH₃), 538 (M⁺ –OCH₃ –CH₃COOH, base peak). *Anal.* Calcd for C₃₄H₄₇NO₁₀: C, 64.84; H, 7.52; N, 2.22. Found: C, 64.69; H, 7.69; N, 2.23. NMR and MS spectra of **10** were identical with those of an authentic sample reported by Takayama *et al.*⁶)

3-O-(S-Methyl)thiocarbonyljesaconitine (17) Compound 17 was prepared from 6 in 92% yield in the same manner as used for the synthesis of compound 8: amorphous powder. IR $\nu_{\rm max}^{\rm KBr}$ cm⁻¹: 3450 (OH), 1725 (C=O). ¹H-NMR δ: 1.11 (3H, t, J=7.1 Hz, NCH₂CH₃), 1.39 (3H, s, OCOCH₃), 2.56 (3H, s, SCH₃), 3.18 (3H, s, OCH₃), 3.20 (3H, s, OCH₃), 3.26 (3H, s, OCH₃), 3.74 (3H, s, OCH₃), 3.87 (3H, s, OCH₃ of anisoyl group), 4.84 (1H, d, J=4.9 Hz, C14- β -H), 5.71 (1H, dd, J=12.7, 7.7 Hz, C3- β -H), 6.93 and 7.98 (each 2H, d, J=8.7 Hz, anisoyl group). ¹³C-NMR δ : 18.8 (SCH₃), 81.7 (C3), 214.7 (C=S). MS m/z: 765 (M⁺), 734 (M⁺-OCH₃, base peak), 674 (M⁺-OCH₃-CH₃COOH).

Deoxyjesaconitine (11) Compound **11** was prepared from **17** in 93% yield in the same manner as used for the synthesis of compound **9**: colorless needles (acetone), mp: 175—176 °C. IR $v_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3500 (OH), 1715 and 1710 (C=O). ¹H-NMR δ: 1.08 (3H, t, J=7.0 Hz, NCH₂CH₃), 1.43 (3H, s, OCOCH₃), 3.17 (3H, s, OCH₃), 3.28 (3H, s, OCH₃), 3.30 (3H, s, OCH₃), 3.74 (3H, s, OCH₃), 3.88 (3H, s, OCH₃ of anisoyl group), 4.83 (1H, d, J=5.0 Hz, C14- β -H), 6.92 and 7.97 (each 2H, d, J=8.0 Hz,

anisoyl group). MS m/z: 659 (M⁺), 628 (M⁺-OCH₃, base peak), 568 (M⁺-OCH₃-CH₃COOH). NMR and MS spectra of 11 were identical with those of an authentic sample.⁷⁾

3,13,15-Tri-O-(S-methyl)thiocarbonyliesaconitine (12) A mixture of 6 (50 mg), dry THF (6 ml), imidazole (3 mg) and NaH (116 mg) was stirred at 0°C for 30 min, then CS₂ (1.2 ml) and CH₃I (0.9 ml) were added dropwise. The mixture was refluxed for 1.5 h, then the reaction was quenched with ice-water and the whole was extracted with CHCl3. The CHCl₃ extract was washed with water, then dried over anhydrous sodium sulfate. The solvent was evaporated off and the residue was purified by column chromatography on silica gel with Et₂O saturated with 28% ammonia water-hexane (3:2) as an eluting solvent to yield 12 (65 mg, 93% yield): amorphous powder. IR $v_{\text{max}}^{\text{KBr}}$ cm⁻¹: 3450 (OH), 1715 (C=O). ¹H-NMR δ : 1.18 (3H, t, J = 7.1 Hz, NCH₂CH₃), 1.28 (3H, s, OCOCH₃), 2.46 (3H, s, SCH₃), 2.57 (3H, s, SCH₃), 2.66 (3H, s, SCH₃), 3.18, 3.19, 3.29, 3.38 (3H, s, OCH₃), 3.83 (3H, s, OCH₃ of anisoyl group), 4.18 (1H, d, J = 5.8 Hz, C15- β -H), 5.30 (1H, d, J = 5.4 Hz, C14- β -H), 5.73 (1H, dd, $J=11.1, 7.4 \text{ Hz}, \text{ C}3-\beta-\text{H}), 6.95 \text{ and } 8.21 \text{ (each 2H, d, } J=9.1 \text{ Hz, anisoyl}$ group). $^{13}\text{C-NMR}$ δ : 18.9, 19.4 and 19.7 (SCH₃ × 3), 81.3 (C3), 88.2 (C13), 87.6 (C15), 214.0, 214.8 and 217.1 (C=S). MS m/z: 945 (M⁺), 914 (M^+-OCH_3) , base peak), 854 $(M^+-OCH_3-CH_3COOH)$. **3,13,15-Trideoxyjesaconitine** (13) A solution of 12 (30 mg) in dry

benzene (1 ml) was refluxed with n-Bu₃SnH (0.2 ml) in dry benzene (0.5 ml) for 4 h. The reaction mixture was concentrated in vacuo, then the residue was chromatographed on silica gel with Et₂O saturated with 28% ammonia water-hexane (4:1) as an eluting solvent and crystallized from Et₂O–hexane to give **13** (18 mg, 88% yield), mp 151—152 °C (lit.8) 153—154 °C). IR $\nu_{\rm max}^{\rm KBr}$ cm⁻¹: 1717 (C=O). $[\alpha]_{\rm D}^{1.9}$ + 29.8° (c=0.98, CHCl₃). ¹H-NMR δ : 1.08 (3H, t, J=7.1 Hz, NCH₂CH₃), 1.39 (3H, s, OCOCH₃), 3.17 (3H, s, OCH₃), 3.26 (3H, s, OCH₃), 3.28 (3H, s, OCH₃), 3.38 (3H, s, OCH₃), 3.83 (3H, s, OCH₃ of anisoyl group), 5.03 (1H, t, $J=4.8 \,\text{Hz}$, C14- β -H), 6.91 and 8.01 (each 2H, d, $J=8.9 \,\text{Hz}$, anisoyl group). 13 C-NMR δ : 85.0 (C1), 26.3 (C2), 34.8 (C3), 39.2 (C4), 49.1 (C5), 82.8 (C6), 44.9 (C7), 85.8 (C8), 49.2 (C9), 43.9 (C10), 50.3 (C11), 28.9 (C12), 39.0 (C13), 75.8 (C14), 37.8 (C15), 83.3 (C16), 63.6 (C17), 80.4 (C18), 53.7 (C19), 49.1 (NCH₂CH₃), 13.4 (NCH₂CH₃), 56.5 (C1'), 57.8 (C6'), 56.0 (C16'), 59.0 (C18'), 55.3 ($COC_6H_4OCH_3$), 169.7 ($COCH_3$), 21.8 (COCH₃), 166.0 (COC₆H₄OCH₃), 163.3, 131.6, 122.8 and 113.6 $(COC_6H_4OCH_3)$. MS m/z: 627 (M⁺), 596 (M⁺ – OCH₃, base peak), 536 $(M^+ - OCH_3 - CH_3COOH)$. HR-MS: Calcd for $C_{35}H_{49}NO_9$: 627.3407. Found: 627.3394. Anal. Calcd for C₃₅H₄₉NO₉·H₂O: C, 65.10; H, 7.96; N, 2.17. Found: C, 65.11; H, 7.71; N, 2.16. NMR and MS spectra of 13 were identical with those of foresaconitine as reported by Chen and Breitmaier8) and Yang et al.9)

3,13,15-Tri-*O*-(*S*-methyl)thiocarbonylaconitine (18) Compound 18 was prepared from 2 in 83% yield in the same manner as used for the synthesis of compound 12: colorless prism (Et₂O–hexane), mp 239—241 °C. IR $\nu_{\rm max}^{\rm KBr}$ cm⁻¹: 1717 (C=O). ¹H-NMR δ: 1.15 (3H, t, J=7.0 Hz, NCH₂CH₃), 1.27 (3H, s, OCOH₃), 2.45 (3H, s, SCH₃), 2.56 (3H, s, SCH₃), 2.66 (3H, s, SCH₃), 3.16 (3H, s, OCH₃), 3.18 (3H, s, OCH₃), 3.29 (3H, s, OCH₃), 3.45 (3H, s, OCH₃), 5.31 (1H, d, J=5.3 Hz, C14- β -H), 5.73 (1H, dd, J=12.7, 5.4 Hz, C3- β -H), 7.45—8.20 (5H, m, benzoyl group). ¹³C-NMR δ: 18.9, 19.5 and 19.8 (SCH₃ × 3), 81.3 (C13), 87.7 (C15), 214.1, 214.9 and 217.0 (C=S). MS m/z: 915 (M⁺), 884 (M⁺-OCH₃, base peak), 824 (M⁺-OCH₃-CH₃COOH).

3,13,15-Trideoxyaconitine (19) Compound **19** was prepared from **18** in 83% yield in the same manner as used for the synthesis of compound **13**: colorless needles (Et₂O-hexane). mp 150—151 °C (lit. ¹⁰) 148—150 °C). IR $\nu_{\text{mar}}^{\text{KBr}}$ cm ⁻¹: 1717 (C=O). ¹H-NMR δ: 1.10 (3H, t, J=7.0 Hz, NCH₂CH₃), 1.38 (3H, s, OCOCH₃), 3.17 (3H, s, OCH₃), 3.28 (6H, s, OCH₃×2), 3.37 (3H, s, OCH₃), 5.05 (1H, d, J=5.0 Hz, C14 β -H), 7.39—8.02 (5H, m, benzoyl group). ¹³C-NMR δ: 85.1 (C1), 26.5 (C2), 35.1 (C3), 39.1 (C4), 49.0 (C5), 82.9 (C6), 47.9 (C7), 85.8 (C8), 49.2 (C9), 38.8 (C10), 50.5 (C11), 28.9 (C12), 34.7 (C13), 75.5 (C14), 38.1 (C15), 85.3 (C16), 63.0 (C17), 80.2 (C18), 53.8 (C19), 49.0 (NCH₂CH₃), 13.3 (NCH₂CH₃), 56.6 (C1′), 57.8 (C6′), 56.2 (C16′), 59.1 (C18′), 169.8 (COCH₃), 21.6 (COCH₃), 166.0 (COC₆H₅), 128.3, 129.3 and 132.9 (COC₆H₅). MS m/z: 597 (M⁺), 566 (M⁺—OCH₃, base peak), 506 (M⁺—OCH₃—CH₃COOH). *Anal.* Calcd for C₃₄H₄₇NO₈: C, 68.32; H, 7.92; N, 2.34. Found: C, 67.97; H, 8.03; N, 2.23. These spectral data was identical to those of crassicaudine. ^{10.11})

3,13,15-Tri-O-(S-methyl)thiocarbonylmesaconitine (20) Compound 20 was prepared from 1 in 83% yield in the same manner as used for the synthesis of compound 12: colorless prisms (Et₂O-hexane), mp 233—234 °C. IR $\nu_{\rm max}^{\rm KBr}$ cm⁻¹: 1715 (C=O). ¹H-NMR δ : 1.23 (3H, s,

OCOCH₃), 2.47 (3H, s, NCH₃), 2.57 (3H, s, SCH₃), 2.58 (3H, s, SCH₃), 2.65 (3H, s, SCH₃), 3.17 (3H, s, OCH₃), 3.19 (3H, s, OCH₃), 3.30 (3H, s, OCH₃), 3.44 (3H, s, OCH₃), 5.35 (1H, d, J=5.3 Hz, C14- β -H), 5.72 (1H, dd, J=12.7, 5.4 Hz, C3- β -H), 7.45—8.28 (5H, m, benzoyl group). ¹³C-NMR δ: 18.9, 19.5 and 19.8 (SCH₃ × 3), 81.2 (C3), 88.2 (C13), 87.7 (C15), 214.1, 214.9 and 217.0 (C=S). MS m/z: 901 (M⁺), 870 (M⁺-OCH₃, base peak), 810 (M⁺-OCH₃-CH₃COOH).

3,13,15-Trideoxymesaconitine (21) Compound **21** was prepared from **20** in 83% yield in the same manner as used for the synthesis of compound **13**: colorless needles (Et₂O-hexane). mp 156—157 °C. IR $\nu_{\rm max}^{\rm KBr}$ cm⁻¹: 1715 (C=O). ¹H-NMR δ: 1.37 (3H, s, OCOCH₃), 2.31 (3H, s, NCH₃), 3.17 (3H, s, OCH₃), 3.28 (6H, s, OCH₃×2), 3.38 (3H, s, OCH₃), 5.07 (1H, d, J=5.0 Hz, C14- β -H), 7.40—8.08 (5H, m, benzoyl group). ¹³C-NMR δ: 85.0 (C1), 26.4 (C2), 37.8 (C3), 39.2 (C4), 48.5 (C5), 82.7 (C6), 48.1 (C7), 85.8 (C8), 44.9 (C9), 38.6 (C10), 50.4 (C11), 28.7 (C12), 34.6 (C13), 75.6 (C14), 38.9 (C15), 83.3 (C16), 63.2 (C17), 80.3 (C18), 56.1 (C19), 42.5 (NCH₃), 56.4 (C1'), 58.1 (C6'), 56.5 (C16'), 59.1 (C18'), 169.7 (COCH₃), 21.6 (COCH₃), 166.0 (COC₆H₅), 128.5, 129.5 and 133.0 (COC₆H₅). MS m/z: 583 (M⁺), 552 (M⁺ – OCH₃, base peak), 462 (M⁺ – OCH₃ – CH₃COOH). *Anal.* Calcd for C₃₃H₄₅NO₈: C, 67.90; H, 7.77; N, 2.40. Found: C, 67.87; H, 7.82; N, 2.40.

References

- 1) P. Kulanthaivel and S. W. Pelletier, Tetrahedron, 1989, 4313.
- T. Mori, H. Bando, Y. Kanaiwa, K. Wada, R. Sato and T. Amiya, *Chem. Pharm. Bull.*, 31, 1422 (1983).
- 3) K. Wada, H. Bando, T. Mori, R. Wada, Y. Kanaiwa and T. Amiya, *Chem. Pharm. Bull.*, **33**, 3658 (1985).
- 4) S. Sakai, H. Takayama, K. Yamaguchi, N. Ide and T. Okamoto, Yakugaku Zasshi, 104, 731 (1984).
- D. H. R. Barton and S. W. McCombie, J. Chem. Soc., Perkin Trans. J. 1975, 1574.
- H. Takayama, S. Hasegawa, S. Sakai, J. Haginiwa and T. Okamoto, Yakugaku Zasshi, 102, 525 (1982).
- T. Mori, H. Bando, Y. Kanaiwa, K. Wada and T. Amiya, Chem. Pharm. Bull., 31, 2884 (1983).
- 8) W. S. Chen and E. Breitmaier, Chem. Ber., 144, 394 (1981).
- 9) C.-R. Yang, X.-H. Hao, D.-Z. Wang and J. Zhou, *Acta Chim. Sinica.*, **39**, 147 (1981).
- 10) F. P. Wang and S. W. Pelletier, J. Nat. Prod., 50, 55 (1987).
- 11) L. Shide and G. Rucker, Planta Med., 52, 412 (1986).